Glypican-1 protein: A core marker for early detection of pancreatic cancer and isolation of circulating exosomes

Author: Senior Product Manager of UA Views：19

This article focuses on the molecular characteristics and biological functions of Glypican-1 (GPC1), systematically elaborating its specific enrichment features as a cell surface proteoglycan in cancer cell-derived exosomes, analyzing the diagnostic sensitivity and specificity of GPC1-positive circulating exosomes as non-invasive biomarkers for pancreatic cancer, and exploring the application value of GPC1 in tumor burden monitoring, surgical prognosis assessment, and early screening.

Recent Advances
Product Information

Recent Advances

Glypican-1 Protein: A Core Marker for Early Detection of Pancreatic Cancer and Isolation of Circulating Exosomes

Summary: This article focuses on the molecular characteristics and biological functions of Glypican-1 (GPC1), systematically elaborating on its specific enrichment characteristics in cancer cell-derived exosomes as a cell surface proteoglycan, analyzing the diagnostic sensitivity and specificity of GPC1-positive circulating exosomes as non-invasive biomarkers for pancreatic cancer, and discussing the application value of GPC1 in tumor burden monitoring, surgical prognosis assessment, and early screening.

I. Research Background on Exosomes and Circulating Tumor Biomarkers.

Exosomes are lipid bilayer-enclosed extracellular vesicles that contain proteins and nucleic acids. They are secreted by all cells and circulate in the blood. Currently, there is a lack of specific detection and isolation of circulating cancer cell-derived exosomes. A biology team from The University of Texas MD Anderson Cancer Center published a study titled “Glypican-1 identifies cancer exosomes and detects early pancreatic cancer” in Nature, using mass spectrometry analysis to identify the cell surface proteoglycan——glypican-1 (GPC1), which is particularly enriched in cancer cell-derived exosomes. This discovery provides a new molecular tool to address the technical bottleneck of specific identification and isolation of circulating tumor exosomes.

II. Specific Enrichment of GPC1 in Cancer Cell Exosomes.

The study used flow cytometry monitoring and isolation of GPC1-positive circulating exosomes from serum of patients and cancer-bearing mice. GPC1-positive circulating exosomes were detected in the serum of pancreatic cancer patients with absolute specificity and sensitivity, thereby distinguishing healthy subjects from patients with benign pancreatic diseases and those with early and late-stage pancreatic cancer. The levels of GPC1-positive circulating exosomes correlated with tumor burden and patient survival before and after surgery.

GPC1-positive circulating exosomes from patients and mice with spontaneous pancreatic tumors carried specific KRAS mutations and reliably detected pancreatic intraepithelial neoplasia in mice, despite negative signals on magnetic resonance imaging. GPC1-positive circulating exosomes can serve as a potential non-invasive diagnostic and screening tool for detecting early stages of pancreatic cancer to facilitate potentially curative surgical treatment. These findings established GPC1 as a pan-specific marker for cancer exosomes.

III. GPC1-Positive Circulating Exosomes as Non-Invasive Biomarkers for Pancreatic Cancer.

GPC1-positive circulating exosomes are non-invasive biomarkers for pancreatic cancer. Among healthy donors, breast cancer patients, and pancreatic ductal adenocarcinoma patients, the percentages of GPC1-positive exosome beads were significantly different. The frequency of KRAS mutations was detected in 47 tumors and verified by DNA sequencing chromatograms. After flow cytometry isolation of GPC1-positive and GPC1-negative circulating exosomes, GPC1 immunogold labeling of circulating exosomes from 3 pancreatic ductal adenocarcinoma patients was confirmed. Significant differences were found in the Ct values of KRAS G12D/G12V, KRAS wild-type mRNA, and 18S ribosomal RNA expression between GPC1-positive and GPC1-negative circulating exosomes. The percentages of GPC1-positive exosome beads in the discovery and validation groups and ROC curve analysis further validated their diagnostic value.

IV. Association Between Circulating GPC1-Positive Exosome Levels and Prognosis After Pancreatic Cancer Resection.

The levels of circulating GPC1-positive exosomes can indicate pancreatic cancer resection outcomes. Through longitudinal blood collection before and after surgery, the percentages of GPC1-positive circulating exosomes differed among patients with benign pancreatic diseases, pancreatic precancerous lesions, or pancreatic ductal adenocarcinoma. Kaplan-Meier curves showed that patients with a decrease in GPC1-positive circulating exosomes greater than or equal to the median decrease had significantly different overall survival and disease-specific survival rates compared to patients with a decrease less than the median decrease. In contrast, patients with a CA19-9 decrease greater than or equal to the median and those with a CA19-9 decrease less than the median showed weaker discriminatory ability for overall and disease-specific survival after resection. These results indicate that GPC1-positive circulating exosomes are a superior prognostic marker compared to CA19-9.

V. Advantages of GPC1-Positive Circulating Exosomes in Early Detection of Pancreatic Cancer.

GPC1-positive circulating exosomes can predict pancreatic cancer in genetically engineered mouse models. Longitudinal blood collection was performed in control mice and PKT mice at 4, 5, 6, 7, and 8 weeks of age. The percentages of GPC1-positive circulating exosomes from PKT and control mice were significantly different. The MRI tumor-enclosed area correlated with tumor volume and the percentage of GPC1-positive circulating exosomes in PKT mice at designated ages. ROC curve analysis of 4-week-old control mice and acute pancreatitis mice versus 4-week-old PKT mice showed that GPC1-positive circulating exosomes can effectively distinguish pancreatic cancer from benign pancreatic diseases. In blood collected from 16- or 20-day-old control and PKT mice, the percentages of GPC1-positive exosome beads were different. Correlation analysis between histopathological scores and GPC1-positive circulating exosome levels, as well as correlation analysis between PKT mouse age and GPC1-positive circulating exosome levels, both confirmed the sensitivity and specificity of GPC1-positive circulating exosomes in early detection.

Routine screening for pancreatic ductal adenocarcinoma using MRI or computed tomography would be very expensive and associated with high false-positive rates. GPC1-positive circulating exosomes detected the possibility of pancreatic cancer in 16-day-old mice, when pancreatic histology was not evident and MRI findings were not apparent. These results suggest the use of GPC1-positive circulating exosomes as a detection and monitoring tool for pancreatic cancer, with emphasis on early detection. Although KRAS mutations may be driver mutations in pancreatic cancer and are detected in early PanIN-1 lesions, it is estimated that it may take 15 to 20 years before early PanIN lesions transform into pancreatic ductal adenocarcinoma. However, pancreatic ductal adenocarcinoma currently presents with non-specific clinical symptoms, so up to 80% of patients have metastases at the time of diagnosis. The lack of specific serum biomarkers and the retroperitoneal location of the pancreas pose challenges for early detection of pancreatic cancer. If the tumor is detected early, pancreaticoduodenectomy can be curative. Due to the late diagnosis of pancreatic cancer, only about 15% of patients present with surgically resectable tumors.

VI. Conclusion.

In GPC1-related basic research and clinical application development, high-quality recombinant GPC1 protein is a core tool for elucidating its binding mechanism with exosome membranes and developing specific detection tools. In response to the needs for GPC1 functional research and detection method development, UA provides Glypican 1/GPC1 His Tag Protein, Human. This product is suitable for application scenarios such as binding activity analysis of GPC1 with exosome membrane components, screening and evaluation of GPC1-specific antibodies, establishment and validation of GPC1-positive exosome detection methods, and research on early diagnostic biomarkers for pancreatic cancer.

Glypican-1, as a proteoglycan specifically enriched on the surface of cancer cell exosomes, has become a highly promising biomarker in the field of non-invasive diagnosis and screening of pancreatic cancer, owing to its unique localization on the exosome membrane, its high correlation with KRAS mutations, and its diagnostic performance superior to traditional markers in early detection of pancreatic cancer. From the isolation and detection of GPC1-positive circulating exosomes to their association with tumor burden and surgical prognosis, from early prediction in genetically engineered mouse models to ROC curve analysis in clinical validation groups, GPC1 continues to drive innovative exploration in the field of early detection of pancreatic cancer. Glypican 1/GPC1 His Tag Protein, Human provides reliable tool support for GPC1-related mechanism research and detection tool development, and will continue to facilitate in-depth development in the fields of early diagnosis and precision medicine for pancreatic cancer.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next